TRANSLATE

The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Practice-changing abstracts for GvHD from ASH 2019

Featured:

Mohamad MohtyMohamad Mohty

Dec 16, 2019


The GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this interview, Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR, discusses practice-changing abstracts in the field of graft-versus-host disease that were presented during ASH 2019.

Mohamad Mohty talks about the benefits of stem cell transplantations and explains that it comes at a cost of complications such as graft-versus-host disease. He also discusses different prophylaxis regimens that are offered to patients and how that affects patient responses. He talks about the success of post-transplant cyclophosphamide in the haploidentical setting and questions its efficacy if it were to be translated into the identical sibling/unrelated setting. He also discusses the anticipated results of the HOVON trial. He concludes by discussing novel interventions such as the use of fecal microbiota transplant.

Practice-changing abstracts for GvHD from ASH 2019